Clarity Peptide Labs: inside the hormone assay

DSIP and the cortisol result

In a 1989 experiment in men, DSIP reduced an antibody-based measure of ACTH in blood plasma for at least three hours. Cortisol was unaffected and followed its normal daily decline. ACTH usually prompts the adrenal glands to release cortisol, so this is a result worth lingering over.

The paper calls the measurement ACTH-like immunoreactivity: material recognised by the assay's antibodies. That exact description matters. I had mentally translated a lower ACTH result into a quieter stress response before reaching the cortisol finding. The experiment supports the narrower statement about the blood measurement; it leaves the broader physiological explanation open.

The unchanged cortisol reading also has a precise meaning. Cortisol continued its usual daily pattern rather than showing an additional DSIP effect. Nothing here measures how worried the men felt, how well they slept or whether daily life became easier.

Inside the assay

An assay is a test designed to detect or measure something particular. The awkward noun after “measured” can carry more information than a confident summary about brain health. In this case, the antibody response and the cortisol measurement describe different observations in the same experiment.

I trust the ACTH measurement within its own narrow scope. “Stress control” reaches too far. There is a genuine human observation here, and an unresolved explanation. The review of DSIP’s unresolved biology adds another difficulty: no confirmed receptor, gene or precursor protein, and weakly documented sleep effects. A receptor is a binding site through which a substance can influence a cell; identifying one would help explain where an effect begins.

The DSIP experiments include a small human sleep study and a newer mouse study of a modified molecule. Each raises a different question from this hormone assay.

Semax and Selank measurements

The same attention to the object being measured opens up quite different stories. With Semax, one rat experiment measured BDNF protein in the basal forebrain; another counted gene-expression changes for nerve-growth factors. The protein and the messages used to make it are distinct measurements.

Selank brings a particularly interesting disagreement in scale. A review of rat-brain membrane experiments describes effects on GABA binding that vary with the binding site and concentration. A separate stressed-rat experiment with diazepam measured anxious behaviour. Reconciling those observations seems more urgent to me than promising how someone would feel.

There is also a human-serum enzyme experiment involving both peptides. Its human material can make it sound closer to patient care than it was: the work happened outside the body. The serum comparison gives that experiment room of its own.

Safety and status

None of these peptides has FDA approval for human use. Semax and Selank have prescription registration in Russia, with Semax also registered in Ukraine; DSIP has no medicine approval. Research material lacks the medicine checks discussed in the existing safety record, and lasting human safety remains uncertain.

The safety questions cover those gaps. For me, clarity begins with leaving an interesting laboratory observation at its actual size.